1. Generics Bulletin
  2. >>Conferences

Amphastar Continues To Push Proprietary Portfolio With Focus On Baqsimi

The Company Expects Several Regulatory Milestones In 2025

 
• By Adam Zamecnik

Amphastar’s leadership has discussed its strategy and latest results as part of a fireside chat at this year’s Jefferies Healthcare Conference, restating its expectations of potential approvals of its GLP-1 candidate in 2025.

(Shutterstock)

Amphastar is continuing in its shift towards a more proprietary portfolio through the development of new products with different delivery systems, as discussed in a fireside chat at this year’s Jefferies Healthcare Conference – which took place in London in late November – in which members of Amphastar’s management focused on the company’s latest results and recent efforts.

Attended by Amphastar’s executive vice president of corporate administration Jacob Liawatidewi and chief financial officer Bill Peters, the chat partly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Conferences

More from Generics Bulletin

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By Dave Wallace

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By Dean Rudge

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.